Cargando…

Experience with the use of siltuximab in patients with SARS-CoV-2 infection

OBJECTIVES: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. PATIENTS AND METHODS: Retrospective re...

Descripción completa

Detalles Bibliográficos
Autores principales: Meira, Fernanda, Albiach, Laia, Carbonell, Cristina, Martín-Oterino, José-Ángel, Martín-Ordiales, Mercedes, Linares, Laura, Macaya, Irene, Agüero, Daiana, Ambrosioni, Juan, Bodro, Marta, Cardozo, Celia, Chumbita, Mariana, De la Mora, Lorena, García-Pouton, Nicole, Garcia-Vidal, Carolina, González-Cordón, Ana, Hernández-Meneses, Marta, Inciarte, Alexy, Laguno, Montserrat, Leal, Lorna, Morata, Laura, Puerta-Alcalde, Pedro, Rico, Verónica, Letona, Laura, Cózar-Llistó, Alberto, Dueñas, Gerard, Solá, Montserrat, Torres, Berta, Rojas, Jhon, Moreno, Antonio, Moreno-García, Estela, Torres, Manuel, Martínez, José A, Soriano, Alex, García, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329576/
https://www.ncbi.nlm.nih.gov/pubmed/33982984
http://dx.doi.org/10.37201/req/045.2021
_version_ 1783732536731500544
author Meira, Fernanda
Albiach, Laia
Carbonell, Cristina
Martín-Oterino, José-Ángel
Martín-Ordiales, Mercedes
Linares, Laura
Macaya, Irene
Agüero, Daiana
Ambrosioni, Juan
Bodro, Marta
Cardozo, Celia
Chumbita, Mariana
De la Mora, Lorena
García-Pouton, Nicole
Garcia-Vidal, Carolina
González-Cordón, Ana
Hernández-Meneses, Marta
Inciarte, Alexy
Laguno, Montserrat
Leal, Lorna
Morata, Laura
Puerta-Alcalde, Pedro
Rico, Verónica
Letona, Laura
Cózar-Llistó, Alberto
Dueñas, Gerard
Solá, Montserrat
Torres, Berta
Rojas, Jhon
Moreno, Antonio
Moreno-García, Estela
Torres, Manuel
Martínez, José A
Soriano, Alex
García, Felipe
author_facet Meira, Fernanda
Albiach, Laia
Carbonell, Cristina
Martín-Oterino, José-Ángel
Martín-Ordiales, Mercedes
Linares, Laura
Macaya, Irene
Agüero, Daiana
Ambrosioni, Juan
Bodro, Marta
Cardozo, Celia
Chumbita, Mariana
De la Mora, Lorena
García-Pouton, Nicole
Garcia-Vidal, Carolina
González-Cordón, Ana
Hernández-Meneses, Marta
Inciarte, Alexy
Laguno, Montserrat
Leal, Lorna
Morata, Laura
Puerta-Alcalde, Pedro
Rico, Verónica
Letona, Laura
Cózar-Llistó, Alberto
Dueñas, Gerard
Solá, Montserrat
Torres, Berta
Rojas, Jhon
Moreno, Antonio
Moreno-García, Estela
Torres, Manuel
Martínez, José A
Soriano, Alex
García, Felipe
author_sort Meira, Fernanda
collection PubMed
description OBJECTIVES: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. PATIENTS AND METHODS: Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab. RESULTS: The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%). CONCLUSIONS: Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein.
format Online
Article
Text
id pubmed-8329576
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-83295762021-08-20 Experience with the use of siltuximab in patients with SARS-CoV-2 infection Meira, Fernanda Albiach, Laia Carbonell, Cristina Martín-Oterino, José-Ángel Martín-Ordiales, Mercedes Linares, Laura Macaya, Irene Agüero, Daiana Ambrosioni, Juan Bodro, Marta Cardozo, Celia Chumbita, Mariana De la Mora, Lorena García-Pouton, Nicole Garcia-Vidal, Carolina González-Cordón, Ana Hernández-Meneses, Marta Inciarte, Alexy Laguno, Montserrat Leal, Lorna Morata, Laura Puerta-Alcalde, Pedro Rico, Verónica Letona, Laura Cózar-Llistó, Alberto Dueñas, Gerard Solá, Montserrat Torres, Berta Rojas, Jhon Moreno, Antonio Moreno-García, Estela Torres, Manuel Martínez, José A Soriano, Alex García, Felipe Rev Esp Quimioter Original OBJECTIVES: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. PATIENTS AND METHODS: Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab. RESULTS: The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%). CONCLUSIONS: Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein. Sociedad Española de Quimioterapia 2021-05-13 2021 /pmc/articles/PMC8329576/ /pubmed/33982984 http://dx.doi.org/10.37201/req/045.2021 Text en © The Author 2021 https://creativecommons.org/licenses/by-nc/4.0/Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Original
Meira, Fernanda
Albiach, Laia
Carbonell, Cristina
Martín-Oterino, José-Ángel
Martín-Ordiales, Mercedes
Linares, Laura
Macaya, Irene
Agüero, Daiana
Ambrosioni, Juan
Bodro, Marta
Cardozo, Celia
Chumbita, Mariana
De la Mora, Lorena
García-Pouton, Nicole
Garcia-Vidal, Carolina
González-Cordón, Ana
Hernández-Meneses, Marta
Inciarte, Alexy
Laguno, Montserrat
Leal, Lorna
Morata, Laura
Puerta-Alcalde, Pedro
Rico, Verónica
Letona, Laura
Cózar-Llistó, Alberto
Dueñas, Gerard
Solá, Montserrat
Torres, Berta
Rojas, Jhon
Moreno, Antonio
Moreno-García, Estela
Torres, Manuel
Martínez, José A
Soriano, Alex
García, Felipe
Experience with the use of siltuximab in patients with SARS-CoV-2 infection
title Experience with the use of siltuximab in patients with SARS-CoV-2 infection
title_full Experience with the use of siltuximab in patients with SARS-CoV-2 infection
title_fullStr Experience with the use of siltuximab in patients with SARS-CoV-2 infection
title_full_unstemmed Experience with the use of siltuximab in patients with SARS-CoV-2 infection
title_short Experience with the use of siltuximab in patients with SARS-CoV-2 infection
title_sort experience with the use of siltuximab in patients with sars-cov-2 infection
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329576/
https://www.ncbi.nlm.nih.gov/pubmed/33982984
http://dx.doi.org/10.37201/req/045.2021
work_keys_str_mv AT meirafernanda experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT albiachlaia experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT carbonellcristina experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT martinoterinojoseangel experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT martinordialesmercedes experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT linareslaura experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT macayairene experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT aguerodaiana experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT ambrosionijuan experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT bodromarta experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT cardozocelia experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT chumbitamariana experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT delamoralorena experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT garciapoutonnicole experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT garciavidalcarolina experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT gonzalezcordonana experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT hernandezmenesesmarta experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT inciartealexy experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT lagunomontserrat experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT leallorna experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT moratalaura experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT puertaalcaldepedro experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT ricoveronica experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT letonalaura experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT cozarllistoalberto experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT duenasgerard experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT solamontserrat experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT torresberta experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT rojasjhon experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT morenoantonio experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT morenogarciaestela experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT torresmanuel experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT martinezjosea experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT sorianoalex experiencewiththeuseofsiltuximabinpatientswithsarscov2infection
AT garciafelipe experiencewiththeuseofsiltuximabinpatientswithsarscov2infection